Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anacetrapib in Homozygous Familial Hypercholesterolemia
NCT01841684Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Primary completion
- Jun 2014
01
Overview
A Phase 3 trial of anacetrapib in homozygous familial hypercholesterolemia (HoFH), sponsored by Merck & Co.. Started Jun 2013; status: terminated.
02
Drugs
anacetrapib
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT01841684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01841684.